Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GOCOVRI Clear all
Completed Phase 4 Interventional Results available

Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome

NCT01112683
View directory record Official record
Conditions
Down Syndrome
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 32 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

NCT00584948
View directory record Official record
Conditions
Fragile X-Associated Tremor/Ataxia Syndrome, Fragile X Premutation Carriers
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

NCT03860597
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
Interventions
Memantine, Placebos
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 12, 2026, 4:47 AM EDT
Terminated Not applicable Interventional Results available

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

NCT00794313
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Amantadine 300 mg, Topiramate, Sugar Pill
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

Memantine for Spasticity in MS Patients

NCT00638027
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
placebo, memantine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

NCT00106405
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
National City, California • Baltimore, Maryland • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS

NCT00586573
View directory record Official record
Conditions
ADHD
Interventions
memantine hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SUVN-502, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199
View directory record Official record
Conditions
Walking Impairment, Multiple Sclerosis
Interventions
ADS-5102, 137 mg, ADS-5102, 274 mg, Placebo
Drug · Other
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
78
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 4 Interventional

Modeling Impaired Judgement in Cocaine Abusers - 6

NCT00015236
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Amantadine
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 12, 2026, 4:47 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of ADS-5102 in PD Patients With LID

NCT02202551
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
Interventions
ADS-5102
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 12, 2026, 4:47 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

NCT00462228
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

NCT03567057
View directory record Official record
Conditions
Multiple Sclerosis, Walking Impairment
Interventions
ADS-5102, 274 mg
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
82
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 12, 2026, 4:47 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512
View directory record Official record
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 12, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Results available

Memantine for Recurrent Glioblastoma

NCT01260467
View directory record Official record
Conditions
Glioblastoma
Interventions
memantine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 2 Interventional

A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)

NCT01372449
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
Evdokia Anagnostou
Individual
Eligibility
6 Years to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 12, 2026, 4:47 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

The Use of Memantine for Prevention of Alzheimer's Disease

NCT05063851
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memantine Hydrochloride Tablets, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
50 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Memantine and Naltrexone Treatment for Opioid Dependence

NCT00125515
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 12, 2026, 4:47 AM EDT
Withdrawn Phase 4 Interventional

Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)

NCT00127114
View directory record Official record
Conditions
Dementia
Interventions
Amantadine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 4 Interventional

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

NCT00330655
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
16 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2007 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder

NCT00956085
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Prepulse Inhibition of Startle in Cocaine Dependence - 7

NCT00015249
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Amantadine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 12, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

NCT00566852
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Memantine, Placebo, Whole brain radiation therapy
Drug · Other · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
229
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 12, 2026, 4:47 AM EDT